Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
NA Rizvi, J Mazières, D Planchard… - The lancet …, 2015 - thelancet.com
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
NA Rizvi, J Mazières, D Planchard… - The Lancet …, 2015 - providence.elsevierpure.com
Background: Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
NA Rizvi, J Mazières, D Planchard… - The Lancet …, 2015 - pure.johnshopkins.edu
Background: Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
[HTML][HTML] Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer …
NA Rizvi, J Mazières, D Planchard… - The Lancet …, 2015 - ncbi.nlm.nih.gov
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
NA Rizvi, J Mazières, D Planchard… - The Lancet …, 2015 - europepmc.org
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
NA Rizvi, J Mazières, D Planchard… - The Lancet …, 2015 - ohsu.elsevierpure.com
Background: Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
[引用][C] Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer …
NA Rizvi, J Mazières, D Planchard… - The Lancet …, 2015 - cir.nii.ac.jp
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with
advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2 …
advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2 …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe… - The Lancet …, 2015 - infona.pl
Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments
have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 …
have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 …
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe… - The Lancet …, 2015 - Elsevier
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
[PDF][PDF] Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung c ancer …
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe… - 2015 - academia.edu
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …